Recombinant human IFN-γ protein - Bioactive cytokine

Human IFN-γ protein - E. coli -expressed, tag-free, with HSA

Recombinant human IFN-γ is a high-quality and biologically active cytokine, validated using proprietary IFN-γ reporter cells. This cytokine also known as type II interferon is produced in E. coli and thoroughly purified to remove endotoxins.

Recombinant human IFN-γ can be used together with HEK-Blue™ IFN-γ cells for the screening of inhibitory molecules, such as Emapalumab, a monoclonal antibody that targets IFN-γ and prevents its binding to its receptor (see figures).

IFN-γ signaling and biological functions

Key features

• Each lot is validated using HEK-Blue™ IFN-γ cells
• Endotoxin < 0.1 EU/µg
• 0.2 µm sterile-filtered

Applications

• Standard for IFN-γ detection and quantification assays
• Screening and release assays for antibodies blocking IFN-γ signaling
• Screening and release assays for engineered IFN-γ

Interferon gamma (IFN-γ) is a pro-inflammatory cytokine that plays a key role in innate and adaptive immune responses to intracellular pathogens and tumor immnuosurveillance.

 More details

InvivoGen’s products are for research use only, and not for clinical or veterinary use.

Figures

SDS PAGE of the recombinant human (h)IFN-γ cytokine. 1.5 μg of IFN-γ was loaded on a 12% Mini-PROTEAN® TGX StainFree™ Precast Gel (Bio-Rad). Detection was performed as per the manufacturer’s instructions. A band was detected at ~17 kDa.

Dose-response in HEK-Blue™ IFN-γ cells to recombinant hIFN-γ cytokine. Cells were stimulated with increasing concentrations of recombinant human (h)IFN-γ. After overnight incubation, the NF-κB-induced SEAP activity was determined using QUANTI-Blue™, a SEAP detection reagent. Data are shown as optical density (OD) at 650 nm (mean ± SEM).

Specifications

Source: E. coli

Species: Human

Alternative names: Type II IFN, Immune interferon

Carrier: HSA (human serum albumin)

Tag: Tag-free

Accession number: P01579

Molecular weight: ~ 17 kDa (SDS-PAGE)

Solubility: 100 μg/ml in water

Formulation: Phosphate buffer saline (pH 7.4), 5% saccharose, 2% HSA

Sterility: 0.2 µm filtration

Form: Lyophilized

Reconstitution buffer: Endotoxin-free water (provided)

Purity: ≥95% (SDS-PAGE)

Endotoxin level: ≤ 0.1 EU/μg (measurement by kinetic chromogenic LAL assay)

Tested applications: Cellular assays

Quality control: Each lot is functionally tested and validated

Contents

• 20 μg of recombinant human IFN-γ provided as a white lyophilized powder.
• 1.5 ml endotoxin-free water.

Recombinant human IFN-γ is shipped at room temperature.

Upon receipt, the product should be stored at -20°C.

 Avoid repeated freeze-thaw cycles.

Details

IFN-γ background

IFN-γ, also known as Type II IFN or immune interferon, is predominantly produced by innate immune cells, such as Natural Killer (NK) cells and innate lymphoid type 1 cells (ILC1), and activated adaptive immune cells, such as Th1 CD4+ T cells and cytotoxic CD8+ T cells [1]. This cytokine is produced as a secreted homodimeric molecule in response to infections and growing tumors [1, 2]. IFN-γ engages a receptor composed of two IFN-γR1 chains and two IFNγ-R2a, thus forming a hexameric complex [2]. While IFN-γR1 is constitutively expressed on all nucleated cells, the expression of IFNγ-R2 is tightly regulated. The binding of IFN-γ to its receptors triggers a JAK1/JAK2 signal transduction leading to the activation of STAT1. Activated STAT1 forms homodimers that are translocated to the nucleus where they bind interferon-gamma-activated sites (GAS) in the promoter of interferon-stimulated genes (ISGs). ISGs encode many products with direct effector or regulatory immune functions [1]. Thus IFN-γ plays a versatile role in immune responses and tissue homeostasis [1].

Relevance for therapeutics development

IFN-γ contributes to the pathogenesis of autoinflammatory diseases, such as haemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS). These diseases are caused by genetic disorders occurring in childhood with life-threatening inflammation [3]. Emapalumab is a fully human monoclonal antibody (mAb) that targets both free and receptor-bound IFN-γ, preventing downstream signaling. This therapeutic antibody was FDA-approved in 2018 for treating pediatric and adult patients with HLH [3]. 

The administration of recombinant IFN-γ is a strategy for enhancing anti-infectious and anti-tumoral innate and adaptive immune responses.
Interferon gamma-1b (Actimmune®) is a form of recombinant human IFN-γ approved by the FDA to treat infections associated with chronic granulomatous disease and to slow the progression of severe malignant osteopetrosis [4]. IFN-g monotherapy to treat cancer has been of limited success. This is partly explained by IFN-γ's short half-life and dual anti- and pro-tumor activities [5, 6]. Multiple clinical trials are ongoing to explore the combination of IFN-γ with other cancer therapeutics [6].
Another strategy relies on the engineering of IFN-γ partial agonists to tune IFN-γ receptor signaling output. Interestingly, such recombinant IFN-γ variants can exhibit biased gene-expression profiles, such as the retention of upregulation of class I molecules and impaired induction of inhibitory checkpoint molecules by cancer cells [2]. These results demonstrate that the two opposing functions of IFN-γ in the tumor microenvironment can be decoupled, offering a route for therapeutic applications.

References:

1. Ivashkiv L.B., 2018. IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 18(9):545-558
2. Mendoza, J.L., et al., 2019. Structure of the IFNγ receptor complex guides design of biased agonists. Nature. 567(7746):56-60.
3. Vallurupalli M. & Berliner N., 2019. Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis. Blood. 134(21):1783-1786.
4. Silva, A.C. & Lobo, J.M. Sousa., 2020. Cytokines and growth factors. Current Applications of Pharmaceutical Biotechnology. 87-113.
5. Castro, F., et al., 2018. Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion. Front Immunol. 9:847.
6. Yi, M., et al., 2024. Targeting cytokine and chemokine signaling pathways for cancer therapy. Signal Transduction and Targeted Therapy. 9(1):176.